BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2021 4:22:54 PM | Browse: 355 | Download: 571
 |
Received |
|
2020-08-31 07:21 |
|
Peer-Review Started |
|
2020-08-31 07:21 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-03 23:52 |
|
Revised |
|
2020-11-16 05:46 |
|
Second Decision |
|
2020-11-25 11:52 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-29 22:23 |
|
Articles in Press |
|
2020-11-29 22:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-12-08 09:17 |
|
Typeset the Manuscript |
|
2021-01-24 00:26 |
|
Publish the Manuscript Online |
|
2021-01-26 16:22 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Effectiveness of entecavir to prevent hepatocellular carcinoma development is genotype dependent in hepatitis B virus-associated liver cirrhosis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kazuo Tarao, Akito Nozaki, Makoto Chuma, Masataka Taguri and Shin Maeda |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Kanagawa Association of Medical and Dental Practitioners |
|
|
| Corresponding Author |
Kazuo Tarao, MD, PhD, Director, Department of Gastroenterology, Tarao’s Gastroenterological Clinic, 2-58-6, Taiyo Building Futamatagawa, Asahi-ku,, Yokohama City 241-0821, Japan. duoluoweih7@gmail.com |
| Key Words |
Hepatocellular carcinoma; Entecavir; Genotype of hepatitis B virus; Oral nucleos(t)ide analogue |
| Core Tip |
Entecavir was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) associated liver cirrhosis. The reduction rate of HCC differs in various regions of the world. We surveyed the differences based on published articles using PubMed (2004-2019). On entecavir administration, the incidence of HCC in genotype D regions (1.89 ± 0.28%/year, mean ± SE) was significantly lower than that in genotype C regions (2.91 ± 0.24%/year, P < 0.01). While, concerning the initial HBV-deoxyribonucleic acid levels, that in genotype C patients was nearly the same as that in genotype D patients. The effectiveness of entecavir to prevent HCC development in patient with HBV-associated liver cirrhosis is genotype dependent. |
| Publish Date |
2021-01-26 16:22 |
| Citation |
Tarao K, Nozaki A, Chuma M, Taguri M, Maeda S. Effectiveness of entecavir to prevent hepatocellular carcinoma development is genotype dependent in hepatitis B virus-associated liver cirrhosis. World J Hepatol 2021; 13(1): 144-150 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i1/144.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i1.144 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
